What is Oral Cancer?

Oral cancer develops in the tissues of the mouth—lips, gums, tongue, inner cheeks, palate, or the area behind wisdom teeth. In India, it ranks as the leading cancer in men due to widespread tobacco and betel nut use. The disease progresses silently; most patients are diagnosed at advanced stages when treatment becomes complex and outcomes worsen.

The cancer arises from squamous cells that line the mouth (in 90% of cases) or occasionally from minor salivary glands. Early detection is key. A persistent sore, lump, or color change in the mouth lasting more than three weeks warrants immediate evaluation. When caught early—before spread to lymph nodes or distant organs—surgery alone or combined with radiation offers the best chance of cure with minimal functional loss.

India faces a dual challenge: high incidence paired with late-stage diagnosis. Awareness campaigns, tobacco control measures, and accessible screening at primary health centers remain essential. Treatment has evolved significantly; immunotherapy and targeted drugs now complement traditional surgery and radiation, improving survival rates even for advanced cases.

Types of Oral Cancer

Warning Signs of Oral Cancer

1. Persistent Mouth Sore: Any ulcer or sore in the mouth that does not heal within 3 weeks; may be red, white, or a mix of both colors.
2. Lump or Thickening: A hard, raised lump on the tongue, cheek, or any part of the mouth; often painless in early stages, discovered accidentally during chewing.
3. Pain or Discomfort: Unexplained pain when chewing, swallowing, or talking; may feel like a sharp sting or constant ache that worsens with movement.
4. Color Changes: Red or white patches (erythroplakia or leukoplakia) that persist for more than three weeks; may appear velvety or slightly raised.
5. Bleeding Without Cause: Blood in saliva, spontaneous bleeding from the mouth, or bleeding gums that cannot be attributed to brushing or flossing.
6. Loose Teeth: Sudden loosening of healthy teeth without gum disease; occurs when cancer invades the jaw bone and loosens the tooth roots.
7. Difficulty Swallowing: Pain or difficulty swallowing solid food or saliva; sensation of food getting stuck in the throat or behind the breastbone.
8. Jaw Stiffness: Limited mouth opening (trismus); difficulty chewing hard foods or yawning; feels like the jaw is locked or stuck.
9. Voice Changes: Persistent hoarseness, slurred speech, or a change in voice quality lasting longer than two weeks; may indicate involvement of deeper throat structures.
10. Swollen Lymph Nodes: Lumps or swelling in the neck, jaw, or under the chin that do not shrink within three weeks; may feel hard and painless.
11. Numbness or Tingling: Abnormal sensation (paresthesia) in the tongue, lips, chin, or gums; indicates possible nerve involvement by the tumor.

Any sign lasting three weeks or longer requires evaluation by an oral surgeon, dentist, or ENT specialist. Early reporting significantly improves treatment outcomes.

Risk Factors for Oral Cancer

Tobacco and betel nut use dominate the risk profile in India. Other factors contribute to disease development. Understanding your risk allows for early detection and prevention.

Data: GLOBOCAN 2022, ICMR Registry, WHO reports on oral cancer in South Asia.

How Oral Cancer is Diagnosed

Diagnosis begins with clinical examination and often requires tissue confirmation. Staging assesses disease extent to guide treatment.

Oral Cancer Staging (AJCC 8th Edition) (AJCC 8th Edition)

Staging is based on TNM classification: Tumor size (T), regional lymph node involvement (N), and distant metastasis (M). Stages range from 0 (carcinoma in situ) to IV (advanced disease).

HPV-positive tumors have improved prognosis (approximately 15-25% better survival) and may undergo treatment de-escalation in research settings. Final stage also incorporates grade and margin status at pathology.

Treatment Options for Oral Cancer

Surgery

Surgery is the primary treatment for most oral cancers, particularly early-stage disease (Stages I-II). The goal is complete removal of the tumor with adequate margins (typically ≥5 mm of healthy tissue) while preserving function. Wide local excision (WLE) is the standard technique for oral cavity tumors. For cancers of the tongue, glossectomy (partial or near-total tongue removal) may be necessary; for buccal or palatal cancers, wide excision with or without underlying bone removal is performed.

Neck dissection—surgical removal of regional lymph nodes—is often performed alongside primary tumor resection to reduce recurrence risk and improve staging accuracy. In early-stage disease with clinically negative lymph nodes, elective neck dissection (removing nodes prophylactically) remains controversial but is increasingly recommended for tumors >2 mm depth or high-grade histology. Comprehensive neck dissection (levels I-V) removes all nodes and associated tissues; selective neck dissection targets specific node levels based on primary tumor location.

Mandibulectomy (removal of jaw bone) is performed when tumor invades cortical bone. Reconstruction with bone flaps (fibula, tibia, or ilium) or soft tissue flaps (pectoralis major, rectus abdominis) restores function and appearance. Reconstruction is resource-intensive and requires expertise; many centers in India lack adequate reconstructive capacity. Complications include infection, flap failure, and functional deficits (chewing, speaking, swallowing).

• Local anesthesia (lidocaine, bupivacaine) for minor procedures
• General anesthesia for extensive resections
• Prophylactic antibiotics (amoxicillin-clavulanate, clindamycin) to prevent surgical site infection
• Topical hemostatic agents (thrombin, fibrin sealant) to control bleeding during surgery

Radiation Therapy

Radiation therapy (RT) is delivered as external beam radiation using linear accelerators. Intensity-modulated radiation therapy (IMRT) is the gold standard; it uses multiple beams of varying intensities to conform high radiation doses to the tumor while minimizing exposure to healthy tissues (salivary glands, bone, soft palate). Conventional 2D or 3D conformal radiation is less precise and used in centers lacking IMRT capacity.

Dosing is typically 70 Gray (Gy) in 35 fractions over 7 weeks for primary tumor treatment. Nodal regions receive 50-66 Gy depending on risk. Hypofractionated regimens (fewer fractions, higher dose per fraction) are explored for palliation or in resource-limited settings but are less well-studied for oral cancer. Brachytherapy (internal radiation using radioactive implants) is occasionally used for early-stage tongue or floor-of-mouth cancers but requires specialized expertise and infrastructure.

Radiation is used in three settings: (1) Adjuvant (after surgery) for high-risk features (positive margins, perineural invasion, advanced nodal disease, extranodal extension); (2) Concurrent with chemotherapy (chemoradiation) for unresectable or advanced disease; (3) Primary (without surgery) for unfit patients or those refusing surgery, though outcomes are inferior. Acute toxicities include mucositis (mouth sores), dysphagia (difficulty swallowing), and skin erythema. Late toxicities (≥3 months post-treatment) include xerostomia (dry mouth), fibrosis, trismus, and rarely osteoradionecrosis (bone death).

• Cisplatin 40 mg/m² weekly (during concurrent chemoradiation) to sensitize tumor to radiation
• Supportive care: mouth rinses (saltwater, chlorhexidine), topical anesthetics (benzocaine rinse), antimicrobial lozenges
• Nutritional support: enteral feeding via nasogastric or PEG tube if dysphagia severe
• Hyposalivation management: artificial saliva, pilocarpine (stimulates residual salivary gland function)

Chemotherapy

Chemotherapy is used in three settings: neoadjuvant (before surgery), concurrent with radiation, or in recurrent/metastatic disease. The standard regimen for advanced oral cancer is cisplatin and 5-fluorouracil (5-FU), often abbreviated as PF. Cisplatin is a platinum compound that crosslinks DNA, causing cell death. 5-FU is an antimetabolite that interferes with DNA and RNA synthesis. The combination achieves response rates of 50-70% in locally advanced disease.

Dosing: Cisplatin 75-100 mg/m² IV on day 1, 5-FU 750-1000 mg/m²/day continuous infusion days 1-5, repeated every 3 weeks for 3-4 cycles. In concurrent chemoradiation, cisplatin is often given weekly at lower doses (40 mg/m²) to reduce toxicity. Neoadjuvant PF × 3 cycles followed by surgery ± adjuvant radiation improves survival compared to surgery alone in stage III-IV disease, particularly if nodal disease is present.

Side effects of chemotherapy are significant: neutropenia (low white blood cells, increasing infection risk), anemia, thrombocytopenia, nephrotoxicity (kidney damage), ototoxicity (hearing loss), neuropathy (nerve damage causing numbness in hands/feet), nausea, and mucositis. Monitoring of blood counts (CBC), kidney function (creatinine, BUN), and hearing (audiometry) is mandatory. Antiemetics (ondansetron, dexamethasone) prevent nausea. Hydration and mesna (kidney protectant) reduce cisplatin toxicity. Dose modifications or treatment delays are common in resource-limited settings due to reduced blood counts.

• Cisplatin 75-100 mg/m² IV every 3 weeks (or 40 mg/m² weekly during chemoradiation)
• 5-Fluorouracil 750-1000 mg/m²/day continuous infusion (days 1-5 every 3 weeks)
• Antiemetics: ondansetron 8 mg IV/PO three times daily, dexamethasone 4 mg daily
• Mesna 600 mg/m² IV to reduce bladder toxicity
• Supportive antibiotics if neutropenia develops (e.g., fluoroquinolone prophylaxis or empiric ceftriaxone if febrile)

Targeted Therapy & Immunotherapy

Cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), is approved for advanced or recurrent oral cancer. It is combined with radiation (in patients who cannot tolerate or have contraindications to cisplatin) or with chemotherapy. Cetuximab plus 5-FU/cisplatin is an alternative to cisplatin/5-FU alone in metastatic disease. Response rates are modest (30-50%), but it is less toxic than chemotherapy.

Immunotherapy using checkpoint inhibitors has emerged as a breakthrough for recurrent and metastatic oral cancer. Nivolumab (anti-PD-1) and pembrolizumab (anti-PD-1) block inhibitory signals on immune cells, allowing T-cells to attack cancer. FDA approval followed impressive response rates in HPV-positive and HPV-negative disease. In India, nivolumab and pembrolizumab are increasingly available but remain expensive. Combination of anti-PD-1 with anti-CTLA-4 (ipilimumab) shows higher response rates but greater toxicity.

Targeted therapies against specific mutations (e.g., BRAF, RAS) are under investigation. Angiogenesis inhibitors (bevacizumab, sunitinib) reduce tumor blood supply but show limited single-agent activity. The future of oral cancer treatment lies in precision medicine—identifying biomarkers (HPV status, PD-L1 expression, tumor mutational burden) that predict response to immunotherapy or targeted drugs. HPV-positive tumors respond better to immunotherapy (50-60% response rate) than HPV-negative tumors (20-30%).

• Cetuximab 400 mg/m² IV loading dose, then 250 mg/m² weekly
• Nivolumab 3 mg/kg IV every 2 weeks or 240 mg IV every 2 weeks (flat dose)
• Pembrolizumab 200 mg IV every 3 weeks or 400 mg IV every 6 weeks
• Ipilimumab 1 mg/kg IV every 3 weeks (with nivolumab for combination therapy)
• Bevacizumab 15 mg/kg IV every 3 weeks (in combination with chemotherapy)

Why Adjuvant Treatment Matters

Adjuvant therapy—chemotherapy or radiation given after surgery—improves survival by 10-25% in high-risk oral cancer. High-risk features include positive surgical margins (cancer cells at the edge of the resected specimen), perineural invasion (cancer cells infiltrating nerves), advanced nodal disease (N2-N3 or extranodal extension), depth of invasion >10 mm, and lymphovascular invasion. Roughly 40-60% of patients with locally advanced oral cancer have at least one high-risk feature; these patients benefit significantly from adjuvant therapy despite the added toxicity and cost burden.

Adjuvant radiation reduces locoregional recurrence (cancer returning in the mouth or neck) from 40-50% to 20-30%. When chemotherapy is combined with adjuvant radiation (chemoradiation), local control improves further, but toxicity is substantial. Xerostomia, difficulty swallowing, and trismus are common late complications. In resource-limited India, adjuvant radiation access is improving but remains unavailable in many regions. Systemic chemotherapy alone (without concurrent radiation) is less effective but is sometimes offered when radiation capacity is limited. The trade-off between treatment aggressiveness and quality of life must be individualized based on patient age, performance status, and preferences.

A Day at HealOnco: Your Oral Cancer Journey

Cost of Oral Cancer Treatment in India

Treatment costs vary widely based on disease stage, hospital tier (government vs. private), and whether reconstruction is needed. Government hospitals offer subsidized care but have limited capacity. Private centers provide timely treatment and advanced technology at higher cost. Costs below are approximate for 2026.

Costs exclude travel, accommodation, and lost wages. Government hospitals (AIIMS, cancer centers) offer heavily subsidized care but have long waiting lists. Private centers offer faster access and modern technology. Insurance coverage varies; some policies cap cancer treatment reimbursement. Schemes like Ayushman Bharat (PMJAY) cover up to ₹5 lakh per family annually; some states add top-ups. Discuss costs and financial options with hospital administration before treatment.

Our Oral Cancer Specialists

Our Centres

Modern vs. Traditional Approaches

Advantages & Limitations of Each Treatment

Surgery: Best chance of cure if margins are negative; avoids long-term radiation toxicity (xerostomia, mucositis); single-modality treatment for early disease is cost-effective. Limitations: significant functional loss if extensive (speech, swallowing, chewing); requires skilled reconstructive surgeons; morbidity in elderly; delayed healing in smokers or diabetics.

Radiation Therapy (IMRT): Avoids surgical mutilation for unfit or unresectable patients; non-invasive; can treat large or infiltrative tumors; repeated doses allow normal tissue recovery. Limitations: 6-8 weeks of daily treatment (time-consuming, logistics-intensive); irreversible late toxicity (xerostomia in 90%, trismus in 20%); increased risk of second cancers (5-10 years post-RT); high upfront cost.

Concurrent Chemoradiation: Superior local control compared to RT alone; chemotherapy acts as radiosensitizer. Limitations: severe acute toxicity (mucositis, dysphagia, fatigue); high hospitalization rate; increased hematologic toxicity; contraindicated in renal impairment or hearing loss; 20-30% of patients cannot complete planned course.

Chemotherapy (Cisplatin/5-FU): Systemic drug delivery treats micrometastases; improves survival in advanced disease; well-studied regimen with known toxicity profile. Limitations: significant side effects (bone marrow suppression, kidney damage, neuropathy, nausea); requires careful monitoring and supportive care; not effective as monotherapy for local disease; substantial cost burden.

Immunotherapy (Nivolumab/Pembrolizumab): Novel mechanism; durable responses (benefit may persist after stopping treatment); less toxic than chemotherapy; effective in HPV-positive and HPV-negative disease. Limitations: expensive (₹300,000–500,000 per cycle in private sector); response rate only 30-40% (majority of patients don’t benefit); immune-related adverse events (colitis, pneumonitis, hepatitis) can be severe; long lag time to response (8-12 weeks); limited access in India outside major cities.

Combination Approaches (Surgery + Radiation): Surgery addresses primary tumor with good local control; adjuvant radiation reduces nodal recurrence. Limitations: cumulative morbidity (both modalities cause dysfunction); longer treatment timeline; substantial cost; may overwhelm healthcare infrastructure in resource-limited settings.

Neoadjuvant Chemotherapy + Surgery + Adjuvant Radiation: Sequential approach allows dose optimization; chemotherapy shrinks large tumors, facilitating surgery; three-modality approach maximizes cure in advanced disease. Limitations: very intensive; high cumulative toxicity; long treatment duration (6+ months); patient burden enormous; suitable only for fit, motivated patients; requires multidisciplinary expertise.

Palliative Care (Advanced/Metastatic): Focuses on symptom management (pain, dysphagia, bleeding); improved quality of life; psychosocial support; sometimes extends survival with minimal toxicity. Limitations: not curative; societal stigma in India around ‘giving up’; patient and family may demand aggressive treatment even if futile; requires training in difficult conversations (not always available).

Managing Treatment Side Effects

Read the full side effects guide for Oral Cancer →

What Our Patients Say

Patient Stories

Video testimonials coming soon. We are working with patients who have completed treatment and are willing to share their journey on camera.

Frequently Asked Questions

Oral Cancer Treatment in Top Cities

Oral Cancer Treatment Cost by City

Cost pages for each city are being prepared and will link here once live. In the meantime, email info.healonco@gmail.com with your diagnosis details for a city-specific estimate.

Related Cancers We Treat

Supportive Care at HealOnco

References

1. GLOBOCAN 2022: Global Cancer Observatory—Oral Cancer Incidence & Mortality globocan.iarc.who.int
2. ICMR—National Cancer Registry Programme: Incidence Trends of Oral Cancer in India www.icmr.gov.in
3. AJCC Cancer Staging Manual, 8th Edition: Head and Neck Cancers (Lip, Oral Cavity, Pharynx) www.cancerstaging.org
4. National Comprehensive Cancer Network (NCCN): Head and Neck Cancers Clinical Practice Guidelines www.nccn.org
5. Patel et al. (2020): Oral Cavity Cancer in India—Epidemiology, Risk Factors, and Management. The Lancet Oncology, 21(10), e502–e514. www.thelancet.com
6. Argiris et al. (2008): Chemotherapy in Head and Neck Cancer. Nature Reviews Clinical Oncology, 5(11), 646–658. www.nature.com
7. Gillison et al. (2019): Efficacy of Nivolumab in Recurrent and Metastatic Head and Neck Cancer: An Updated Meta-analysis (CheckMate-141). The Lancet Oncology, 20(2), 1-13. www.thelancet.com
8. American Society of Clinical Oncology (ASCO): Head and Neck Cancer Guideline Updates www.asco.org
9. WHO: Oral Cancer Prevention & Detection—Global Burden of Disease Report 2022 www.who.int
10. Indian Head and Neck Oncology Society (IHnos): Consensus Guidelines on Management of Oral Cancer in Resource-Limited Settings www.ihons.org
11. PubMed Central: Oral Cancer Research Database—Latest Clinical Trials & Evidence-Based Reviews www.ncbi.nlm.nih.gov
12. Cancer Support Community: Oral Cancer Patient Education & Support Resources www.cancersupportcommunity.org